Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.

ABSTRACT: Mother-to-child transmission (MTCT) of HIV-1 remains a global health problem. The World Health Organization (WHO) recommendations advise the administration of a once-daily, oral, prophylactic regimen of the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) from birth until 4 to 6 weeks of age for infants born to HIV-infected mothers in regions without access to safe and nutritionally adequate alternatives to breast milk. A critical factor driving the successful implementation of the WHO guidelines involves sustaining high adherence to the frequent dosing. With these challenges in mind, we have developed the first injectable, sustained-release NVP formulations with the goal of providing, for 6 weeks or longer, preventative plasma drug levels from a single subcutaneous administr

SUBMITTER: Cortez JM 

PROVIDER: S-EPMC4291403 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature